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SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS AND COST 
ANALYSES OF GUIDELINE IMPLEMENTATION STRATEGIES 
 
ABSTRACT 
Objectives 
To appraise the quality of economic studies undertaken as part of evaluations of guideline 
implementation strategies; determine their resources use; and recommend methods to 
improve future studies. 
 
Methods 
Systematic review of economic studies undertaken alongside robust study designs of 
clinical guideline implementation strategies published (1966-1998).  Studies assessed 
against the BMJ economic evaluations guidelines for each stage of the guideline process 
(guideline development, implementation and treatment).   
 
Results 
235 studies were identified, 63 reported some information on cost.  Only 3 studies 
provided evidence that their guideline was effective and efficient.  38 reported the 
treatment costs only, 12 implementation and treatment costs, 11 implementation costs 
alone, and two guideline development, implementation and treatment costs.  No study 
gave reasonably complete information on costs. 
 
Conclusions 
Very few satisfactory economic evaluations of guideline implementation strategies have 
been performed.  Current evaluations have numerous methodological defects and rarely 
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consider all  relevant costs and benefits.  Future evaluations should focus on evaluating 
the implementation of evidence based guidelines.  
 
Keywords:  Cost-effectiveness analysis, physician (or health care professional) 
behaviour, practice guidelines, quality improvement, systematic review. 
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INTRODUCTION  
Access to health care services is only one of a number of determinants of people’s health 
and there are concerns that people cannot gain access to care that is appropriate to 
prevent, maintain and promote health.  These concerns have led to increasing policy 
interest in quality improvement activities across a wide range of health care systems and 
settings.  Clinical practice guidelines are an increasingly common element of such quality 
improvement activities throughout the world.  Guidelines have been defined as  
“systematically developed statements to assist practitioner and patient decisions about 
appropriate health care”.1  They have the potential to improve the care received by 
patients by promoting interventions of proven benefit and discouraging ineffective 
interventions.  However, the development and introduction of guidelines is not itself 
without cost.  Even when they represent effective and cost-effective practice for the 
setting in which they are to be introduced (which is not always the case, particularly in 
relation to cost-effectiveness), their implementation may not be efficient.  In some 
circumstances, the costs of guideline development and introduction are likely to outweigh 
their potential benefits.  In other circumstances, it may be more efficient to adopt less 
costly but less effective implementation strategies.  Local health care organisations have 
relatively few resources for clinical effectiveness activities and policy makers need to 
consider how best to use these to maximise benefits based upon consideration of the 
likely benefits and resources needed for different implementation strategies.  Whilst there 
are a substantial number of systematic reviews of the effectiveness of different guideline 
implementation strategies, none have explicitly reported on the cost-effectiveness of 
different strategies.2-8  
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Economic evaluation is a way of providing information about whether the benefits of 
adopting a course of action compensate for the loss of benefits which would have been 
generated had the best alternative use been made of the limited resources.  It does this by 
undertaking a comparative analysis of alternative courses of action in terms of both their 
costs (resource use) and benefits.9 Bringing costs and benefits together in an economic 
evaluation provides information as to whether:  
• one strategy should be preferred to another as it provides more benefits and uses less 
resources (i.e. is ‘cost-saving’); or  
• the extra benefits obtained by a more costly strategy are worth the extra resources (i.e. 
is ‘cost-effective’).   
 
This paper reports a systematic review of economic evaluations and cost analyses 
undertaken alongside rigorous but non-economic evaluations of guideline implementation 
strategies.  We identify the methods used in such economic studies and their frequency, 
and summarise existing evidence on the efficiency of guideline implementation strategies.  
Where possible we have described the resource use involved in guideline development 
and implementation, as such data may help inform decision-makers as to the likely cost of 
these activities. From this, we draw conclusions about the strengths and weaknesses of the 
existing economic evaluations of guideline implementation and make recommendations 
about how such studies can be improved. 
 
ECONOMIC EVALUATION FRAMEWORK 
In principle, economic evaluations of guideline implementation strategies should be based 
on the same basic principles as an evaluation of a standard health technology (a new drug 
or a new type of surgery).9  A standard health technology assessment limits itself to the 
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consideration of the costs and benefits of providing a treatment (e.g. administering drug A 
or drug B) and the consequences of that treatment.  The evaluation of guideline 
implementation strategies is different in that the breadth of costs and benefits that could 
be considered is wider.  Determining whether the implementation of a guideline is 
worthwhile involves determining (a) whether the practice embodied in the guideline 
represents an efficient use of resources and (b) whether the guideline implementation 
process represents the most efficient way of bringing practice into line with that embodied 
in the guideline.  
 
There are three distinct stages in the introduction of guidelines that could be considered in 
an economic evaluation of guideline implementation:10
1. Development of the guideline; 
2. Implementation of the guideline; and 
3. Treatment effects and costs as a consequence of behaviour change. 
 
The first stage covers the costs and benefits of assembling the data and agreeing the 
guideline recommendations.  From the economic perspective the development should 
only commence once consideration has been given to whether devoting resources to 
improve health care delivery is the best way to improve people’s health.  It should also 
consider whether the recommendations would represent effective and efficient practice 
for the health care provider and the client groups they serve.  The second stage involves 
dissemination of the guideline (e.g. through workshops) or the adoption of active 
implementation strategies (e.g. the use of patient specific reminders).  Activities such as 
the organisation of workshops or reminder systems would involve resource use and may 
also benefit the professional and patient groups involved in the behaviour change process.  
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From an economic perspective the choice of implementation strategies to be evaluated 
should also be influenced by the consideration of the setting in which they are to be 
introduced and an understanding of the relative importance of the different factors 
influencing the health care professionals behaviour (i.e. knowledge of their utility 
function).  The final stage considers the costs and benefits consequent on the behaviour 
change.  For instance, the change in cost, patient well-being and other benefits caused by 
changes in treatment. 
 
Although the structure of an economic evaluation of guideline implementation strategies 
could include the costs and benefits from each of the three stages, it may sometimes be 
legitimate to design an economic evaluation of more limited scope.  For example, it 
would be legitimate to evaluate only the costs and benefits of disseminating and 
implementing a guideline that had already been shown to represent efficient practice in 
the setting in which it is to be applied.11,12  A further reason for legitimately limiting the 
scope of the economic evaluation relates to its perspective.  If a non-societal perspective, 
for example that of the health care provider, is adopted then it may be legitimate to 
exclude costs falling on the patient as well as those benefits gained by health 
professionals in terms of improved knowledge, job satisfaction that may arise during 
development and implementation of the guideline.  A final possible reason for not 
measuring some costs and benefits is when the assumption can be made that their 
inclusion will not change the policy decision.  For example, if it is believed, a priori, that 
a guideline will substantially reduce the costs of treatment while maintaining or 
improving the outcomes of patients it may be felt legitimate to exclude the costs of 
development, and implementation as they could not possibly cancel out any savings in 
treatment costs.  However, this makes it difficult to judge which implementation strategy 
7  
was the most efficient.  Furthermore, this limits the transferability of results to situations 
where the same implementation strategies are compared for a guideline addressing the 
same issues in a similar setting. Whether such limitations are appropriate depends on the 
justification given for the limitation.  Such justification should be explicit and supported 
by appropriate evidence.   
 
The extent that the economic evaluations and cost analyses included in this review have 
considered all costs and benefits from each of the three stages is assessed as part of the 
review.  Where relevant costs and benefits have been excluded, consideration will be 
given to whether their exclusions were justified on the basis of stated perspective, 
unimportance to final conclusions, or previous work showing adoption of the guideline 
recommendation would be efficient.  
 
METHODS 
This review of economic evaluations and cost analyses in evaluations of clinical guideline 
implementation strategies was undertaken as part of a broader review of the effectiveness 
of guideline implementation strategies.13
 
Summary of methods for the review of effectiveness of guideline implementation 
strategies 
Studies were selected for inclusion if they met the following criteria: study design – 
randomised controlled trials (RCT), controlled clinical trials (CCT), controlled before and 
after studies (CBA), or interrupted time series analysis (ITS); intervention – guideline 
implementation strategies; participants – medically qualified health care providers; and 
outcomes – objective measures of provider behaviour and/or patient outcome.  The 
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following databases were searched using an extensive search strategy that was 92% 
sensitive for studies meeting the inclusion criteria:13 MEDLINE (1966-1998); EMBASE 
(1980-1998); HealthSTAR (1975-1998); SIGLE (1980-1998); the Cochrane Controlled 
Trials Register (4th edition 1998) and the register of the Cochrane Effective Practice 
Organisation of Care Group (EPOC).  Studies were not excluded on the basis of language 
and attempts were made to identify unpublished studies e.g. final reports and 
dissertations.  Approximately 150,000 hits were screened by two researchers.  Hard 
copies of 863 potentially relevant studies were retrieved of which 235 met the inclusion 
criteria.  Two reviewers independently undertook detailed data abstraction.   
 
Inclusion criteria for the review of economic evaluations and cost analyses 
For the review of economic evaluations and cost analyses, two reviewers independently 
assessed whether studies reported any economic data.  Studies were included if they 
reported either an economic analysis or cost analysis.  A study was considered to have 
undertaken an economic evaluation if it reported evidence on costs and at least surrogate 
endpoints for effectiveness/benefits.  A study was considered to have undertaken a cost 
analysis if it failed to relate costs to effectiveness/benefits.   
 
Review of methodological quality of economic evaluations and cost analyses 
Included studies were assessed against the British Medical Journal guidelines for 
reviewers of economic evaluations.14  These guidelines are designed to improve the 
quality of economic evaluations and cover three broad areas including study design, data 
collection, and analysis and interpretation of results.  The criteria were not used as a 
scoring system but rather as a common means of summarising those aspects of an 
economic evaluation that are generally considered to be important.  Even though these 
9  
guidelines were published in 1996 it is worth noting they represent refinements to criteria 
that had been developed over 20 year earlier.  If studies only reported cost analyses, they 
were not assessed against the criteria relating to benefits.   
 
Review of results of economic evaluations and cost analyses 
Data were abstracted on resource use and cost of guideline development and 
implementation and any resulting changes in clinical treatment and summarised according 
to the type of implementation strategies adopted. 
 
RESULTS 
Studies reporting cost analyses or economic evaluations 
Sixty three of 235 (27%) studies (involving 78 comparisons) reported economic 
evaluations and cost analyses (see appendix).  Characteristics of the included studies are 
described in Table 1.  The majority of the studies were conducted in the USA and aimed 
to improve management.  Thirty-six studies tried to change 1 behaviour, the remainder 
targeted several behaviours (to a maximum of 6).15   
 
Table 1 about here 
 
Interventions evaluated 
Comparisons were made between more than 2 strategies in several studies (Table 2) and a 
total of 53 different behaviour change strategies were considered (including ‘no 
intervention’ controls).  Forty behaviour change strategies were multifaceted, involving 
more than 1 intervention.  The maximum number of interventions employed was 7.16  
10  
Other than the ‘no intervention’ control only 1 strategy (use of reminders alone) was used 
in more than 10 studies.   
 
Table 2 about here 
 
Methodological quality of economic evaluations 
The methodological quality of the included studies is summarised in Table 3.  Of the 10 
studies that stated the viewpoint of the study 4 took the perspective of the health service, 
17-20 5 that of the hospital or providers,21-25 and only 1 a societal perspective.26 Almost all 
the studies provided some simple rationale for the choice of implementation strategies 
considered.  However, none of the studies reported studying the utility functions of the 
health care professionals in order to determine the design of the implementation strategies 
that were to be evaluated. 
 
The form of economic evaluation was rarely stated.  Even where it was stated it was 
sometimes misleading.  For example, 3 studies reported that they had undertaken ‘cost-
benefit’ analyses.26-28  Two of these presented differences in cost set against differences in 
several measures of effectiveness, without any attempt at aggregation (a design defined in 
this paper as a cost-consequence analysis).26,28 The third undertook a cost analysis.27  
Thirty five of the remaining studies were cost consequence analyses, 11 were cost-
effectiveness analyses and 13 reported some aspect of cost (e.g. staff or material costs) 
but made no effort to relate costs to benefits (cost analyses). 
 
Table 3 about here 
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Data collection criteria 
Sources of effectiveness estimates 
All the studies used experimental or quasi-experimental study designs.  However, 
methodological weaknesses often undermined the effectiveness results.  For example, the 
statistical significance of benefits was uncertain in 16 RCTs, CCTs and CBAs that had 
potential unit of analysis errors and 11 ITS studies were inappropriately analysed in the 
published reports. 
 
Only 5 studies attempted to measure health outcomes.18, 26,29-31  Only 1, using a balance 
sheet approach, attempted to consider any wider benefit either to patients, their families or 
practitioners.26  The reliance on process measures by the majority of studies was of 
uncertain validity as few provided any details of how the evidence base supporting 
recommendations was constructed.  Therefore, it is unclear whether any of the observed 
changes in behaviour improved or maintained patient outcomes or were efficient. 
 
Methods for estimation of costs 
Thirty eight studies only considered the costs consequent on behaviour change (treatment 
costs).  Eleven reported costs of implementation and 12 implementation and treatment.  
Only 2 considered the costs of guideline development, implementation and treatment.26,32  
These 2 studies were amongst the few that attempted to provide descriptions of resource 
use but neither were comprehensive in terms of costs considered.  One did attempt to 
bring uncosted resource use into the decision making process by using a balance sheet 
approach.26  Overall, no study gave reasonably complete information on the estimation of 
cost for guideline development, implementation and treatment. 
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Analysis criteria  
Discounting was not undertaken or mentioned in any of the economic evaluations in 
which it was required and few reported any form of sensitivity analysis.  The sensitivity 
analysis that was conducted was very limited.  For example, in 12 studies sensitivity 
analysis was limited to changes in a single variable (e.g. a cost of a procedure).   
 
In 1 study, initially planned as a cost-effectiveness analysis, the implementation strategy 
was cost saving.25  In all but 11 of the 38 cost-consequences analyses it was concluded 
that the implementation strategy was ‘efficient’. In 3 studies the implementation strategy 
was reported to be more costly but no more effective.28,31,33  These conclusions must 
clearly be treated with suspicion, as must the other conclusions about cost and efficiency, 
given the limitations in methodology, especially the lack of reports on the evidence base 
for the guideline and reporting of the methods used described above.   
 
Summary of resource and cost estimates for guideline development, and 
implementation 
Due to the generally poor quality of reporting of the economic evaluations, data on 
resource use and cost of guideline development and implementation were available for 
only 4 analyses.26,32-34  In one of these studies conducted in the 1970’s and which 
compared audit and feedback with a local consensus process, the estimates of resource 
use may no longer be generalisable.33  Two studies used the preparation and 
dissemination of educational materials along with educational meetings26,32 and one 
provision of reminders.34  A summary of the resource use information reported in these 
studies is available from the authors.   
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DISCUSSION  
By systematically identifying and critiquing the available economic evidence on guideline 
implementation strategies, we have sought to provide information to decision-makers and 
researchers to aid in their deliberation on how best to get guidelines into practice.  A total 
of 63 studies were identified that reported an economic evaluation or cost analysis. The 
multifaceted nature of many of the implementation strategies adopted, the multitude of 
policy issues addressed and the weak methodology adopted by the majority of the studies 
precluded the presentation of results on the efficiency of alternative implementation 
strategies in any meaningful form.   
 
Overall, the methodological quality of the 63 included studies was poor.  This finding is 
similar to other reviews of economic evaluations36 and in part should be expected given 
the loose interpretation of what defines an economic evaluation.  In another recently 
completed review of economic evaluations, studies had to present costing methodology in 
the methods section and results of the economic evaluation in the results section in order 
to be included in the review.37  Had this criteria been applied in this review it would 
undoubtedly have reduced the number of included studies, but it is unlikely that the 
overall conclusion of generally poor methodology would have changed. 
 
One of the main weaknesses of the included studies is the very limited attempts to show 
that the guidelines that were to be implemented would represent effective or efficient 
practice.  This combined with the use of process measures by many of the studies severely 
limits the validity of any conclusions drawn that development and implementation of the 
guideline represents an efficient use of resources.   
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The majority of identified studies considered only the costs of treatment and its 
consequences.  In several cases this limitation in scope would not be expected to change 
the conclusions, as the magnitude of cost savings provided by adopting the recommended 
practice was so large.38-42  Therefore in such cases, other methodological weaknesses 
aside, the evaluation would have been fit for the purpose for which it was designed.  
However, the results of such evaluations are context specific and have limited 
transferability as it is not possible to determine whether the resources used to provide the 
implementation strategies compared within these studies were efficiently used.  
Furthermore, none of the studies reported using any economic rationale to determine the 
design of the implementation strategies.  This leads to further uncertainty about whether 
strategies that had the potential to change behaviour in the desired way were compared.  
 
The results presented in this paper are based on a search strategy that was developed to be 
as comprehensive as possible and over 150,000 abstracts were assessed.  Studies were 
only identified to the end of 1998 and it is possible that more recent studies are of higher 
quality, as guidelines such as those published by the BMJ have become more readily 
available.  Nevertheless, the majority of included studies were published in the 1990s and 
similar guidance had been published years earlier.refs  Williams, Drummond   On the 
whole the studies included in this paper are of a generally low methodological quality 
regardless of when or where the study was conducted and published.   
 
The search strategy was also devised with the intention of identifying those studies based 
on robust study designs.  The study designs chosen were those that, if analysed 
appropriately, could provide the most robust data on effectiveness.  As such data often 
help determine total costs and are integral to estimates of efficiency it is implicit that such 
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studies should provide the best data on which to base, at least, some parts of an economic 
evaluation.  It is possible that the search strategy may not have identified some studies 
that have reported economic data separately or have used data from robust study designs 
to model efficiency.  However, given the limitations in the primary evidence base the 
inclusion of any such studies would not change the findings of this study. 
 
CONCLUSIONS 
Recently a number of agencies, such as the National Institute for Clinical Excellence in 
the UK and the Task Force for Preventive Services in the USA, have explicitly started to 
produce guidelines incorporating evidence on effectiveness and efficiency.45,46  There are 
however still concerns that such national guidance may not represent efficient practice at 
a local level.  Furthermore, it has been shown that the simple production of such evidence 
based guidelines does not appear to change practice,47 which again highlights the need for 
the evaluation of guideline implementation strategies.  However, the paucity of data on 
resource use, cost and efficiency of guideline implementation strategies has been shown 
in this review.  Overall, studies were of poor methodological quality and did not appear to 
consider guidelines based on evidence of effectiveness or efficiency.  Studies also did not 
report an economic rationale for the choice of implementation strategies considered and 
did not cover all stages of guideline implementation that may be relevant.   
 
It is tempting to recommend further large scale studies that can give unbiased estimates of 
costs and effect for all three stage (guideline development, implementation and the 
treatment effects and costs as a consequence of behaviour change).  However, it is 
unlikely that in many cases such studies will be practical due to statistical issues relating 
to sample size requirements.  The approach outlined by Mason et al (1999) and Sculpher 
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(2000) seems more realistic.11,48 They argue that primary studies should concentrate on 
evaluating behaviour change and estimating costs of development and implementation of 
the guideline, while modelling exercises should use these data to determine whether the 
guideline is efficient within the setting considered and at the level of behaviour achieved 
or desired.11,48 
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Table 1 General characteristics of included studies 
Study characteristic  Type Number of studies 
1.  Study design RCT 
Cluster RCT 
ITS 
Other 
10 
24 
18 
11a
2.  Country of origin USA 
UK 
Canada 
Other  
45 
11 
3 
4b
3.  Rationale for study Improve management 
Cost containment 
Both management and cost containment  
36 
19 
8 
4.  Targeted behaviour General management 
Patient education and advice 
Prescribing 
Preventive services 
Referrals 
Test ordering 
Other 
24 
14 
28 
13 
8 
24 
18c
5. Number of groups 
comparedd
Comparison of 2 groups  
Comparison of 3 groups 
Comparison of 4 groups 
35 
4 
6 
6.  Study population Physicians 
Physicians & nurses 
Physicians, nurses, pharmacists 
Physicians, nurses, pharmacists, other 
Physicians, nurses, other 
Physicians, unclear 
Physicians, other 
49 
3 
1 
1 
2 
1 
6 
RCT = randomised controlled trial; ITS = Interrupted Time Series 
a Cluster Controlled before and after design 4; Controlled clinical trial 5; Cluster Controlled clinical 
trial 2 
b Australia 2, New Zealand 1, Thailand 1 
c Procedures 6, Diagnosis 5, Financial 5, Record keeping 1, Discharge planning 1 
d Excluding the 18 ITS studies where a direct comparison was not made 
24  
Table 2 Frequency of employment of behaviour change strategies used by 
abridged Cochrane Effective Practice and Organisation of Care 
Group78 classificationa
Intervention Type Number of times employed 
Audit and Feedback 24 
Consensus process 5 
Educational materials 29 
Educational meetings 25 
Outreach visits 10 
Patient-mediated 3 
Reminders 20 
Other behaviour change interventions 17 
Financial 4 
Organisational 10 
Structural 11 
 
a In the full EPOC list 56 different behaviour change interventions are defined; the 
44 financial, structural and organisational interventions are amalgamated into 
three sub headings as they were rarely employed 
25  
Table 3 Criteria used to assess the quality of economic evaluations and cost 
analyses 
Study design Numbera
1. Research question stated 63 
2. Importance of question stated 60 
3. Viewpoint of analysis: 
• Stated 
• Defined 
 
10 
5 
4. Rationale for choosing alternative programmes or interventions compared stated 61 
5. Alternatives being compared clearly defined 63 
6. Form of economic evaluation used stated 12 
7. Choice of form of economic evaluation justified in relation to question addressed 1 
Data collection  
8. Source(s) of effectiveness estimates stated 63 
9. Details of design and results of effectiveness study given (if based on single study 63 
10. Details of methods of synthesis or meta-analysis of data underpinning guideline 
recommendations 
3 
11. Primary outcome measure(s) for economic evaluation clearly stated 25 
12. Methods to value health states and other benefits stated 5 
13. Details of subjects from whom valuations were obtained given 5 
14. Productivity changes (if included) reported separately  3 
15. Relevance of productivity changes to study question discussed 3 
16. Quantities of resources reported separately from their unit costs 20 
17. Methods for estimation of quantities and units costs described 30 
18. Currency and price data recorded 13 
26  
27  
Table 3 cont 
Data collection (cont)  
19. Details of currency and price adjustments for inflation or currency conversion 
given 
5 
20. Details of any model used 0 
21. Choice of model used and key parameters on which it is based justified 0 
Analysis  
22. Time horizon of costs and benefits stated 48 
23. Discount rate(s) stated 0/38 
24. Choice of rate(s) justified 0/38 
25. Explanation given if costs and benefits are not discounted 0 
26. Details of statistical tests and CI given for stochastic data 16 
27. Approach to sensitivity analysis given 16 
28. Choice of variable for sensitivity analysis justified 5 
29. Ranges of which variables are varied stated 7 
30. Relevant alternatives compared 6 
31. Incremental analysis reported 37 
32. Major outcomes presented in an aggregated as well as a disaggregated form 0 
33. Answer to study question given 60 
34. Conclusions follow from data reported 44 
35. Conclusions accompanied by appropriate caveats 42 
 
a Out of 63 studies except where otherwise noted 
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